ClinicalTrials.gg
CompletedNCT03884101LEAP-001Updated Feb 2, 2026Results posted

Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) Versus Chemotherapy for Endometrial Carcinoma (ENGOT-en9 / MK-7902-001)

A Phase 3 interventional study of Lenvatinib and Pembrolizumab in Endometrial Neoplasms, sponsored by Merck Sharp & Dohme LLC. Completed at 195 sites in 22 countries. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-02-02.

Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
842
Allocation
Randomized
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 15 studies testing lenvatinib in Endometrial Neoplasms — 4 open to participants now, 6 under way, none of them phase 3. lenvatinib · Endometrial Neoplasms.

Enrollment
Largest of 15
842 · median 32
Started
2019
with 1 other
Phase 3
3 of 15
none open now
Registered
6th of 15
by date
Lead sponsor
2 of 15
Merck Sharp & Dohme LLC

Among the 15 studies testing lenvatinib in Endometrial Neoplasms, this one has the largest enrollment, is one of 2 that started in 2019, is one of 3 in phase 3, and was the 6th registered.

Endometrial Neoplasms

1,428 studies on the registry are indexed under Endometrial Neoplasms; 471 are open to participants now.

Browse Endometrial Neoplasms studies →

Open to participants now

4 of the 15 studies testing lenvatinib in Endometrial Neoplasms are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About lenvatinib

lenvatinib: first FDA approval 2015 (LENVIMA), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 357 Endometrial Neoplasms studies recruiting now, 267 (75%) set no upper age limit and 54 (15%) stop at 75 or younger; 26 take children under 18; 23 take healthy volunteers.

This study: 18 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 15 studies testing lenvatinib in Endometrial Neoplasms, or all of them as a file.
02

Study summary

The purpose of this study is to compare the efficacy of pembrolizumab + lenvatinib to chemotherapy in female participants with Stage III, IV, or recurrent endometrial carcinoma. It is hypothesized that the combination of pembrolizumab + lenvatinib will be superior to chemotherapy for progression-free survival (PFS) per Response Evaluation Criteria In Solid Tumors version 1.1 (RECIST 1.1) by blinded independent central review (BICR). It is also hypothesized that the combination of pembrolizumab + lenvatinib will be superior to chemotherapy for overall survival (OS).

As of Amendment 7 eligible participants on study completion will be able to transition to an extension study, if available, in which they can continue to receive pembrolizumab monotherapy, lenvatinib monotherapy, or a combination of both pembrolizumab and lenvatinib as received in the parent study.

03

Conditions studied

  • Endometrial Neoplasms
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Has Stage III, Stage IV, or recurrent, -confirmed endometrial carcinoma with disease that is either measurable or nonmeasurable but radiographically apparent, per version 1.1 (RECIST 1.1) as assessed by blinded independent central review (BICR) (note: may have received prior chemotherapy only if administered concurrently with radiation; may have received prior radiation without concurrent chemotherapy; may have received prior hormonal therapy for treatment of endometrial carcinoma, provided that it was discontinued ≥1 week prior to randomization; and may have received 1 prior line of systemic platinum-based and/or neoadjuvant chemotherapy)
  • Has provided sample or newly obtained core or excisional biopsy of a tumor lesion that was not previously irradiated, for determination of mismatch repair (MMR) status
  • Has an (ECOG) performance status of 0 or 1, as assessed within 7 days prior to the first dose of study intervention
  • Is not pregnant or breastfeeding, and is either not a woman of (WOCBP) or is a WOCBP who agrees to use during the study and for ≥120 days after pembrolizumab, ≥30 days after lenvatinib, or ≥180 days after (chemotherapy) [if a WOCBP, a pregnancy test will be required within 24 hours of first dose of study drug]
  • Has adequately controlled blood pressure within 7 days prior to randomization
  • Has adequate organ function based on assessment within 7 days prior to the first dose of study intervention

Exclusion criteria

Exclusion Criteria:

  • Has carcinosarcoma (malignant mixed Műllerian tumor), endometrial leiomyosarcoma or other high grade sarcomas, or endometrial stromal sarcomas
  • Has a central nervous system (CNS) , unless local therapy (e.g., whole brain radiation therapy, surgery, or radiosurgery) has been completed and have discontinued use of for this indication for ≥4 weeks prior to starting study medication (major surgery within 3 weeks of the first dose of study drug will be exclusionary)
  • Has a known additional (other than endometrial carcinoma) that is progressing or has required active treatment in the last 3 years
  • Has gastrointestinal malabsorption or any other condition that might affect the absorption of lenvatinib
  • Has a pre-existing Grade ≥3 gastrointestinal or nongastrointestinal fistula
  • Has radiographic evidence of major blood vessel invasion/infiltration
  • Has active hemoptysis (bright red blood at ≥0.5 teaspoon) within 3 weeks prior to the first dose of study intervention or tumor bleeding within 2 weeks prior to randomization
  • Has cardiovascular disease within 12 months from first dose of study intervention including Class III or IV congestive heart failure, unstable angina, myocardial infarction or cerebral vascular accident, or cardiac arrhythmia associated with hemodynamic instability
  • Has any infection requiring systemic treatment
  • Has not recovered adequately from any toxicity and/or complications from major surgery prior to randomization
  • Has a known history of (HIV) infection (HIV test is required at screening)
  • Has a known history of (defined as hepatitis B surface antigen [HBsAg] reactive) or known active virus (HCV) [defined as HCV ribonucleic acid (RNA) is detected] (hepatitis B and C testing is required at screening only when mandated by local health authority)
  • Has a history of (noninfectious) pneumonitis that required treatment with steroids, or has current pneumonitis
  • Has a history or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the study, interfere with the participant's participation for the full duration of the study, or is not in the best interest of the participant to participate, in the opinion of the treating investigator
  • Has a known psychiatric or substance abuse disorder that would interfere with cooperation with the requirements of the study
  • Has a diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy (in dosing exceeding 10 mg daily of prednisone equivalent) or any other form of therapy within 7 days prior to randomization
  • Has an active disease (with the exception of psoriasis) that has required systemic treatment in the past 2 years (i.e., with use of disease modifying agents, corticosteroids or immunosuppressive drugs)
  • Has received prior systemic chemotherapy in any setting for the treatment of endometrial carcinoma (note: prior chemotherapy administered concurrently with radiation is permitted)
  • Has received prior radiotherapy within 4 weeks prior to randomization (participants must have recovered from all radiation-related toxicities, not require corticosteroids, and not have had radiation pneumonitis - a 2-week is permitted for palliative radiation to non-CNS disease and vaginal brachytherapy)
  • Has received prior hormonal therapy for the treatment of endometrial carcinoma within 1 week of randomization
  • Has received prior therapy with any treatment targeting vascular endothelial growth factor (VEGF)-directed angiogenesis, an anti-programmed cell death (PD)-1, anti-PD ligand (L)1, or agent, or with an agent directed to another stimulatory or co-inhibitory T-cell receptor (e.g., CTLA-4, OX 40, CD137)
  • Has received a live or within 30 days prior to the first dose of study intervention
  • Has known intolerance to study intervention (or any of the )
  • Has had an allogenic tissue/solid organ transplant
  • Is currently participating in or has participated in a study of an agent or has used an investigational device within 4 weeks prior to randomization
Terms in these criteria, in plain language(22)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
842 participants (actual)

Study arms

  • Experimental
    Lenvatinib + Pembrolizumab

    Participants receive lenvatinib daily and pembrolizumab once at the start of each 3-week treatment cycle.

    Drug: Lenvatinib · Biological: Pembrolizumab

  • Active comparator
    Paclitaxel + Carboplatin

    Participants receive paclitaxel and carboplatin once at the start of each 3-week treatment cycle.

    Drug: Paclitaxel · Drug: Carboplatin

Interventions

  • Lenvatinib 4 mg or 10 mg capsules at a total daily dose of 20 mg taken by mouth once per day.

    Also known as: E7080, MK-7902, LENVIMA®

  • BiologicalPembrolizumab

    Pembrolizumab 200 mg intravenous (IV) infusion given on Day 1 of each cycle.

    Also known as: MK-3475, KEYTRUDA®

  • Paclitaxel 175 mg/m\^2 IV infusion given on Day 1 of each cycle.

    Also known as: TAXOL®, ONXAL®

  • Carboplatin 10 mg/mL IV infusion at a total dose of are-under-the-curve (AUC) 6 (per Calvert's formula) given on Day 1 of each cycle.

    Also known as: PARAPLATIN®

06

What researchers measure

Primary outcomes

  1. Progression-free Survival (PFS) Based on Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as Assessed by Blinded Independent Central Review (BICR) in Mismatch Repair Proficient (pMMR) Participants

    PFS was defined as the time from randomization to the first documented progressive disease (PD) per RECIST 1.1 based on BICR, or death due to any cause, whichever occurred first. Per RECIST 1.1, PD was defined as ≥20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum had to demonstrate an absolute increase of ≥5 mm. The appearance of one or more new lesions was also considered PD. The PFS of pMMR participants was presented.

    Time frame: Up to approximately 44 months

  2. PFS Based on RECIST 1.1 as Assessed by BICR in All Randomized Participants

    PFS was defined as the time from randomization to the first documented PD per RECIST 1.1 based on BICR, or death due to any cause, whichever occurred first. Per RECIST 1.1, PD was defined as ≥20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum had to demonstrate an absolute increase of ≥5 mm. The appearance of one or more new lesions was also considered PD. The PFS of all randomized participants was presented.

    Time frame: Up to approximately 44 months

  3. Overall Survival (OS) in pMMR Participants

    OS was measured from the time of randomization up to death due to any cause. Participants without documented death at the time of the final analysis were to be censored at the date of the last follow-up. The OS for pMMR participants is presented.

    Time frame: Up to approximately 51 months

  4. OS in All Randomized Participants

    OS was measured from the time of randomization up to death due to any cause. Participants without documented death at the time of the final analysis were to be censored at the date of the last follow-up. The OS for all randomized participants is presented.

    Time frame: Up to approximately 51 months

Secondary outcomes

  1. Objective Response Rate (ORR) Based on RECIST 1.1 as Assessed by BICR in pMMR Participants

    ORR was defined as the percentage of participants who had a Complete Response (CR: Disappearance of all target lesions) or a Partial Response (PR: At least a 30% decrease in the sum of diameters of target lesions) as assessed using RECIST 1.1. The percentage of pMMR participants who experienced a CR or PR is presented.

    Time frame: Up to approximately 51 months

  2. ORR Based on RECIST 1.1 as Assessed by BICR in All Randomized Participants

    ORR was defined as the percentage of participants who had a CR: Disappearance of all target lesions or a PR: At least a 30% decrease in the sum of diameters of target lesions as assessed using RECIST 1.1. The percentage of all randomized participants who experienced a CR or PR is presented.

    Time frame: Up to approximately 51 months

  3. Mean Change From Baseline in the Global Health Status/Quality of Life Score of the European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire Core-30 (QLQ-C30) in pMMR Participants

    The EORTC QLQ-C30 was developed to assess the quality of life of patients with cancer. It contains 30 questions (items), 24 of which aggregate into nine multi-item scales representing various aspects, or dimensions, of quality of life (QoL): one global scale, five functional scales (physical, role, cognitive, emotional, and social), 3 symptom scales (fatigue, nausea, pain), and six additional single-symptom items assessing additional symptoms commonly reported by cancer patients (dyspnoea, loss of appetite, insomnia, constipation and diarrhoea) and perceived financial impact of the disease. Individual items are scored on a 4-point scale (1=not at all, 2=a little, 3=quite a bit, 4=very much). Raw scores for each scale are standardized into a range of 0 to 100 by linear transformation; a higher score on the global and functional scales represents a higher ("better") level of functioning, and a higher score on the symptom scale represents a higher ("worse") level of symptoms.

    Time frame: Baseline and up to approximately 18 weeks

  4. Mean Change From Baseline in the Global Health Status/Quality of Life Score of the EORTC QLQ-C30 in All Randomized Participants

    The EORTC QLQ-C30 was developed to assess the quality of life of patients with cancer. It contains 30 questions (items), 24 of which aggregate into nine multi-item scales representing various aspects, or dimensions, of QoL: one global scale, five functional scales (physical, role, cognitive, emotional, and social), 3 symptom scales (fatigue, nausea, pain), and six additional single-symptom items assessing additional symptoms commonly reported by cancer patients (dyspnoea, loss of appetite, insomnia, constipation and diarrhoea) and perceived financial impact of the disease. Individual items are scored on a 4-point scale (1=not at all, 2=a little, 3=quite a bit, 4=very much). Raw scores for each scale are standardized into a range of 0 to 100 by linear transformation; a higher score on the global and functional scales represents a higher ("better") level of functioning, and a higher score on the symptom scale represents a higher ("worse") level of symptoms.

    Time frame: Baseline and up to approximately 18 weeks

  5. Number of Participants Who Experienced an Adverse Event (AE)

    An AE was any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE could have been any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated). Per protocol, the number of participants who experienced one or more AEs was reported for the first course lenvatinib + pembrolizumab and paclitaxel + carboplatin arms.

    Time frame: Up to approximately 68 months

  6. Number of Participants Who Experienced a Serious Adverse Event (SAE)

    An SAE was an AE that resulted in death, was life-threatening, required or prolonged hospitalization, resulted in persistent or significant disability, was a congenital birth defect, or was another important medical event. Per protocol, the number of participants who experienced one or more SAEs was reported for the first course lenvatinib + pembrolizumab and paclitaxel + carboplatin arms.

    Time frame: Up to approximately 68 months

  7. Number of Participants Who Experienced an Immune-Related Adverse Event (irAE)

    An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. Immune-related AEs (irAEs) were AEs that were considered immune-mediated or potentially immune-mediated and are well-documented for pembrolizumab. These irAEs may occur shortly after the first dose or several months after the last dose of pembrolizumab treatment and may affect more than one body system simultaneously. Per protocol, the number of participants who experienced one or more irAEs was reported for the first course lenvatinib + pembrolizumab and paclitaxel + carboplatin arms.

    Time frame: Up to approximately 68 months

  8. Number of Participants Who Discontinued Study Intervention Due to an AE

    An AE was any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE could have been any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated). Per protocol, the number of participants who discontinued any study intervention (pembrolizumab and/or lenvatinib or paclitaxel and/or carboplatin) due to an AE was reported for the first course lenvatinib + pembrolizumab and paclitaxel + carboplatin arms.

    Time frame: Up to approximately 68 months

07

Results

Posted Oct 16, 2024

Participant flow

Of the 842 total participants randomized in the MK-7902-001 global study, 66 were also randomized in the China extension study for MK-7902-001 (NCT04865289).

Participant flow — Overall Study
MilestoneLenvatinib + PembrolizumabPaclitaxel + Carboplatin
Started420422
Treated420411
Received a second course of pembrolizumab170
Completed00
Not completed420422
Withdrew: Death234248
Withdrew: Lost to follow-up11
Withdrew: Physician decision98126
Withdrew: Sponsor decision7932
Withdrew: Withdrawal by subject815

Outcome measures

PrimaryProgression-free Survival (PFS) Based on Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as Assessed by Blinded Independent Central Review (BICR) in Mismatch Repair Proficient (pMMR) Participants

PFS was defined as the time from randomization to the first documented progressive disease (PD) per RECIST 1.1 based on BICR, or death due to any cause, whichever occurred first. Per RECIST 1.1, PD was defined as ≥20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum had to demonstrate an absolute increase of ≥5 mm. The appearance of one or more new lesions was also considered PD. The PFS of pMMR participants was presented.

Time frame:
Up to approximately 44 months
Reported as:
Median · Months
Progression-free Survival (PFS) Based on Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as Assessed by Blinded Independent Central Review (BICR) in Mismatch Repair Proficient (pMMR) Participants
MonthsLenvatinib + PembrolizumabPaclitaxel + Carboplatin
Progression-free Survival (PFS) Based on Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as Assessed by Blinded Independent Central Review (BICR) in Mismatch Repair Proficient (pMMR) Participants9.6 (8.2 to 11.9)10.2 (8.4 to 10.4)
Statistical analysis
  • Lenvatinib + Pembrolizumab vs Paclitaxel + Carboplatin · Log Rank · p = 0.5550121 · Hazard ratio (hr): 1.01 · 95% CI 0.83 to 1.24Based on Cox regression model with Efron's method for tie handling with treatment as a covariate stratified by ECOG performance status and prior chemotherapy and/or chemoradiation.
PrimaryPFS Based on RECIST 1.1 as Assessed by BICR in All Randomized Participants

PFS was defined as the time from randomization to the first documented PD per RECIST 1.1 based on BICR, or death due to any cause, whichever occurred first. Per RECIST 1.1, PD was defined as ≥20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum had to demonstrate an absolute increase of ≥5 mm. The appearance of one or more new lesions was also considered PD. The PFS of all randomized participants was presented.

Time frame:
Up to approximately 44 months
Reported as:
Median · Months
PFS Based on RECIST 1.1 as Assessed by BICR in All Randomized Participants
MonthsLenvatinib + PembrolizumabPaclitaxel + Carboplatin
PFS Based on RECIST 1.1 as Assessed by BICR in All Randomized Participants12.5 (10.3 to 15.1)10.2 (8.4 to 10.4)
Statistical analysis
  • Lenvatinib + Pembrolizumab vs Paclitaxel + Carboplatin · Log Rank · p = 0.1792058 · Hazard ratio (hr): 0.92 · 95% CI 0.77 to 1.10Based on Cox regression model with Efron's method for tie handling with treatment as a covariate stratified by MMR status, ECOG performance status, and prior chemotherapy and/or chemoradiation.
PrimaryOverall Survival (OS) in pMMR Participants

OS was measured from the time of randomization up to death due to any cause. Participants without documented death at the time of the final analysis were to be censored at the date of the last follow-up. The OS for pMMR participants is presented.

Time frame:
Up to approximately 51 months
Reported as:
Median · Months
Overall Survival (OS) in pMMR Participants
MonthsLenvatinib + PembrolizumabPaclitaxel + Carboplatin
Overall Survival (OS) in pMMR Participants30.9 (25.4 to 37.7)29.4 (26.2 to 35.4)
Statistical analysis
  • Lenvatinib + Pembrolizumab vs Paclitaxel + Carboplatin · Log Rank · p = 0.2459875 · Hazard ratio (hr): 1.02 · 95% CI 0.83 to 1.26Based on Cox regression model with Efron's method for tie handling with treatment as a covariate stratified by ECOG performance status and prior chemotherapy and/or chemoradiation.
  • Lenvatinib + Pembrolizumab vs Paclitaxel + Carboplatin · Log Rank · p = 0.5875597 · Hazard ratio (hr): 1.02 · 95% CI 0.83 to 1.26Based on Cox regression model with Efron's method for tie handling with treatment as a covariate stratified by ECOG performance status and prior chemotherapy and/or chemoradiation.
PrimaryOS in All Randomized Participants

OS was measured from the time of randomization up to death due to any cause. Participants without documented death at the time of the final analysis were to be censored at the date of the last follow-up. The OS for all randomized participants is presented.

Time frame:
Up to approximately 51 months
Reported as:
Median · Months
OS in All Randomized Participants
MonthsLenvatinib + PembrolizumabPaclitaxel + Carboplatin
OS in All Randomized Participants37.7 (32.2 to 43.6)32.1 (27.2 to 35.7)
Statistical analysis
  • Lenvatinib + Pembrolizumab vs Paclitaxel + Carboplatin · Log Rank · p = 0.21552 · Hazard ratio (hr): 0.93 · 95% CI 0.77 to 1.12Based on Cox regression model with Efron's method for tie handling with treatment as a covariate stratified by MMR status, ECOG performance status, and prior chemotherapy and/or chemoradiation.
SecondaryObjective Response Rate (ORR) Based on RECIST 1.1 as Assessed by BICR in pMMR Participants

ORR was defined as the percentage of participants who had a Complete Response (CR: Disappearance of all target lesions) or a Partial Response (PR: At least a 30% decrease in the sum of diameters of target lesions) as assessed using RECIST 1.1. The percentage of pMMR participants who experienced a CR or PR is presented.

Time frame:
Up to approximately 51 months
Reported as:
Number · Percentage of Participants
Objective Response Rate (ORR) Based on RECIST 1.1 as Assessed by BICR in pMMR Participants
Percentage of ParticipantsLenvatinib + PembrolizumabPaclitaxel + Carboplatin
Objective Response Rate (ORR) Based on RECIST 1.1 as Assessed by BICR in pMMR Participants50.9 (45.3 to 56.6)55.2 (49.5 to 60.8)
Statistical analysis
  • Lenvatinib + Pembrolizumab vs Paclitaxel + Carboplatin · Stratified Miettinen & Nurminen · p = 0.8569 · Difference in percentage: -4.2 · 95% CI -11.9 to 3.5Based on Miettinen \& Nurminen method stratified by ECOG performance status and prior chemotherapy and/or chemoradiation.
SecondaryORR Based on RECIST 1.1 as Assessed by BICR in All Randomized Participants

ORR was defined as the percentage of participants who had a CR: Disappearance of all target lesions or a PR: At least a 30% decrease in the sum of diameters of target lesions as assessed using RECIST 1.1. The percentage of all randomized participants who experienced a CR or PR is presented.

Time frame:
Up to approximately 51 months
Reported as:
Number · Percentage of Participants
ORR Based on RECIST 1.1 as Assessed by BICR in All Randomized Participants
Percentage of ParticipantsLenvatinib + PembrolizumabPaclitaxel + Carboplatin
ORR Based on RECIST 1.1 as Assessed by BICR in All Randomized Participants56.0 (51.1 to 60.8)56.0 (51.1 to 60.8)
Statistical analysis
  • Lenvatinib + Pembrolizumab vs Paclitaxel + Carboplatin · Stratified Miettinen & Nurminen · p = 0.4999 · Difference in percentage: 0.0 · 95% CI -6.7 to 6.7Based on Miettinen \& Nurminen method stratified by MMR status, ECOG performance status, and prior chemotherapy and/or chemoradiation.
SecondaryMean Change From Baseline in the Global Health Status/Quality of Life Score of the European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire Core-30 (QLQ-C30) in pMMR Participants

The EORTC QLQ-C30 was developed to assess the quality of life of patients with cancer. It contains 30 questions (items), 24 of which aggregate into nine multi-item scales representing various aspects, or dimensions, of quality of life (QoL): one global scale, five functional scales (physical, role, cognitive, emotional, and social), 3 symptom scales (fatigue, nausea, pain), and six additional single-symptom items assessing additional symptoms commonly reported by cancer patients (dyspnoea, loss of appetite, insomnia, constipation and diarrhoea) and perceived financial impact of the disease. Individual items are scored on a 4-point scale (1=not at all, 2=a little, 3=quite a bit, 4=very much). Raw scores for each scale are standardized into a range of 0 to 100 by linear transformation; a higher score on the global and functional scales represents a higher ("better") level of functioning, and a higher score on the symptom scale represents a higher ("worse") level of symptoms.

Time frame:
Baseline and up to approximately 18 weeks
Reported as:
Least squares mean · Scores on a scale
Mean Change From Baseline in the Global Health Status/Quality of Life Score of the European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire Core-30 (QLQ-C30) in pMMR Participants
Scores on a scaleLenvatinib + PembrolizumabPaclitaxel + Carboplatin
Mean Change From Baseline in the Global Health Status/Quality of Life Score of the European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire Core-30 (QLQ-C30) in pMMR Participants-5.10 (-7.76 to -2.45)-1.34 (-4.00 to 1.32)
Statistical analysis
  • Lenvatinib + Pembrolizumab vs Paclitaxel + Carboplatin · cLDA model · p = 0.0302 · Difference in least square means: -3.77 · 95% CI -7.17 to -0.36
SecondaryMean Change From Baseline in the Global Health Status/Quality of Life Score of the EORTC QLQ-C30 in All Randomized Participants

The EORTC QLQ-C30 was developed to assess the quality of life of patients with cancer. It contains 30 questions (items), 24 of which aggregate into nine multi-item scales representing various aspects, or dimensions, of QoL: one global scale, five functional scales (physical, role, cognitive, emotional, and social), 3 symptom scales (fatigue, nausea, pain), and six additional single-symptom items assessing additional symptoms commonly reported by cancer patients (dyspnoea, loss of appetite, insomnia, constipation and diarrhoea) and perceived financial impact of the disease. Individual items are scored on a 4-point scale (1=not at all, 2=a little, 3=quite a bit, 4=very much). Raw scores for each scale are standardized into a range of 0 to 100 by linear transformation; a higher score on the global and functional scales represents a higher ("better") level of functioning, and a higher score on the symptom scale represents a higher ("worse") level of symptoms.

Time frame:
Baseline and up to approximately 18 weeks
Reported as:
Least squares mean · Scores on a scale
Mean Change From Baseline in the Global Health Status/Quality of Life Score of the EORTC QLQ-C30 in All Randomized Participants
Scores on a scaleLenvatinib + PembrolizumabPaclitaxel + Carboplatin
Mean Change From Baseline in the Global Health Status/Quality of Life Score of the EORTC QLQ-C30 in All Randomized Participants-4.52 (-6.84 to -2.20)-2.22 (-4.60 to 0.15)
Statistical analysis
  • Lenvatinib + Pembrolizumab vs Paclitaxel + Carboplatin · cLDA model · p = 0.1355 · Difference in least square means: -2.29 · 95% CI -5.31 to 0.72
SecondaryNumber of Participants Who Experienced an Adverse Event (AE)

An AE was any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE could have been any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated). Per protocol, the number of participants who experienced one or more AEs was reported for the first course lenvatinib + pembrolizumab and paclitaxel + carboplatin arms.

Time frame:
Up to approximately 68 months
Reported as:
Count of participants · Participants
Number of Participants Who Experienced an Adverse Event (AE)
ParticipantsLenvatinib + PembrolizumabPaclitaxel + Carboplatin
Number of Participants Who Experienced an Adverse Event (AE)418405
SecondaryNumber of Participants Who Experienced a Serious Adverse Event (SAE)

An SAE was an AE that resulted in death, was life-threatening, required or prolonged hospitalization, resulted in persistent or significant disability, was a congenital birth defect, or was another important medical event. Per protocol, the number of participants who experienced one or more SAEs was reported for the first course lenvatinib + pembrolizumab and paclitaxel + carboplatin arms.

Time frame:
Up to approximately 68 months
Reported as:
Count of participants · Participants
Number of Participants Who Experienced a Serious Adverse Event (SAE)
ParticipantsLenvatinib + PembrolizumabPaclitaxel + Carboplatin
Number of Participants Who Experienced a Serious Adverse Event (SAE)23084
SecondaryNumber of Participants Who Experienced an Immune-Related Adverse Event (irAE)

An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. Immune-related AEs (irAEs) were AEs that were considered immune-mediated or potentially immune-mediated and are well-documented for pembrolizumab. These irAEs may occur shortly after the first dose or several months after the last dose of pembrolizumab treatment and may affect more than one body system simultaneously. Per protocol, the number of participants who experienced one or more irAEs was reported for the first course lenvatinib + pembrolizumab and paclitaxel + carboplatin arms.

Time frame:
Up to approximately 68 months
Reported as:
Count of participants · Participants
Number of Participants Who Experienced an Immune-Related Adverse Event (irAE)
ParticipantsLenvatinib + PembrolizumabPaclitaxel + Carboplatin
Number of Participants Who Experienced an Immune-Related Adverse Event (irAE)31656
SecondaryNumber of Participants Who Discontinued Study Intervention Due to an AE

An AE was any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE could have been any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated). Per protocol, the number of participants who discontinued any study intervention (pembrolizumab and/or lenvatinib or paclitaxel and/or carboplatin) due to an AE was reported for the first course lenvatinib + pembrolizumab and paclitaxel + carboplatin arms.

Time frame:
Up to approximately 68 months
Reported as:
Count of participants · Participants
Number of Participants Who Discontinued Study Intervention Due to an AE
ParticipantsLenvatinib + PembrolizumabPaclitaxel + Carboplatin
Number of Participants Who Discontinued Study Intervention Due to an AE20380

Adverse events

Collected over Up to approximately 68 months. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
First Course: Lenvatinib + Pembrolizumab233/420 (55.5%)230/420 (54.8%)416/420 (99%)
Paclitaxel + Carboplatin253/422 (60%)84/411 (20.4%)397/411 (96.6%)
Second Course: Lenvatinib + Pembrolizumab3/17 (17.6%)3/17 (17.6%)15/17 (88.2%)
Most frequent serious events
Showing 10 of 283
Most frequent serious events
EventFirst Course: Lenvatinib + PembrolizumabPaclitaxel + CarboplatinSecond Course: Lenvatinib + Pembrolizumab
Intestinal obstructionGastrointestinal disorders4/4202/4111/17
Intra-abdominal haemorrhageGastrointestinal disorders0/4200/4111/17
DiverticulitisInfections and infestations0/4200/4111/17
Urinary tract infectionInfections and infestations9/4203/4111/17
HypokalaemiaMetabolism and nutrition disorders0/4201/4111/17
DiarrhoeaGastrointestinal disorders11/4202/4110/17
HypertensionVascular disorders10/4200/4110/17
AnaemiaBlood and lymphatic system disorders1/4209/4110/17
ColitisGastrointestinal disorders9/4201/4110/17
PneumonitisRespiratory, thoracic and mediastinal disorders9/4200/4110/17
Most frequent other events
Showing 10 of 109
Most frequent other events
EventFirst Course: Lenvatinib + PembrolizumabPaclitaxel + CarboplatinSecond Course: Lenvatinib + Pembrolizumab
HypertensionVascular disorders288/42082/4112/17
HypothyroidismEndocrine disorders261/42010/4113/17
AlopeciaSkin and subcutaneous tissue disorders47/420220/4110/17
DiarrhoeaGastrointestinal disorders214/42097/4112/17
AnaemiaBlood and lymphatic system disorders95/420209/4114/17
NauseaGastrointestinal disorders159/420173/4111/17
ProteinuriaRenal and urinary disorders146/42013/4112/17
FatigueGeneral disorders145/420118/4111/17
Decreased appetiteMetabolism and nutrition disorders144/42082/4110/17
ArthralgiaMusculoskeletal and connective tissue disorders132/42097/4110/17

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Lenvatinib + PembrolizumabPaclitaxel + CarboplatinTotal
Mean62.5 ± 10.164.0 ± 9.163.3 ± 9.7
Sex: Female, Male
Sex: Female, Male(Participants)Lenvatinib + PembrolizumabPaclitaxel + CarboplatinTotal
Female420422842
Male000
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Lenvatinib + PembrolizumabPaclitaxel + CarboplatinTotal
Hispanic or Latino6467131
Not Hispanic or Latino347343690
Unknown or Not Reported91221
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Lenvatinib + PembrolizumabPaclitaxel + CarboplatinTotal
American Indian or Alaska Native000
Asian114102216
Native Hawaiian or Other Pacific Islander011
Black or African American101424
White288300588
More than one race8513
Unknown or Not Reported000
Eastern Cooperative Oncology Group (ECOG) Performance Status
Eastern Cooperative Oncology Group (ECOG) Performance Status(Participants)Lenvatinib + PembrolizumabPaclitaxel + CarboplatinTotal
ECOG=0250240490
ECOG=1170182352
Prior Chemotherapy and/or Chemoradiation
Prior Chemotherapy and/or Chemoradiation(Participants)Lenvatinib + PembrolizumabPaclitaxel + CarboplatinTotal
Yes7468142
No346354700
Mismatch Repair (MMR) Status
Mismatch Repair (MMR) Status(Participants)Lenvatinib + PembrolizumabPaclitaxel + CarboplatinTotal
dMMR100100200
pMMR320322642
08

Study locations

195 sites
  • University of South Alabama, Mitchell Cancer Institute ( Site 0245)
    Mobile, Alabama 36604, United States
  • Arizona Oncology Associates PC- HOPE ( Site 8005)
    Tucson, Arizona 85711, United States
  • UCLA Hematology and Oncology Clinic (Westwood) ( Site 0233)
    Los Angeles, California 90095, United States
  • University of Colorado Cancer Center ( Site 0204)
    Aurora, Colorado 80045, United States
  • Smilow Cancer Hospital at Yale New Haven ( Site 0202)
    New Haven, Connecticut 06511, United States
  • University of Miami Health System ( Site 0249)
    Miami, Florida 33136, United States
  • Georgia Cancer Center at Augusta University ( Site 0222)
    Augusta, Georgia 30912, United States
  • Women's Cancer Care ( Site 0208)
    Covington, Louisiana 70433, United States
  • Maine Medical Partners ( Site 0217)
    Scarborough, Maine 04074, United States
  • Minnesota Oncology Hematology, PA ( Site 8003)
    Minneapolis, Minnesota 55404, United States
  • Memorial Sloan-Kettering Cancer Center At Basking Ridge ( Site 0268)
    Basking Ridge, New Jersey 07920, United States
  • John Theurer Cancer Center at Hackensack University Med Ctr ( Site 0226)
    Hackensack, New Jersey 07601, United States
  • Memorial Sloan Kettering Cancer Center- Monmouth ( Site 0273)
    Middletown, New Jersey 07748, United States
  • MSKCC-Bergen ( Site 0276)
    Montvale, New Jersey 07645, United States
  • Holy Name Medical Center ( Site 0235)
    Teaneck, New Jersey 07666, United States
  • Memorial Sloan-Kettering Cancer Center at Commack ( Site 0267)
    Commack, New York 11725, United States
  • Memorial Sloan Kettering Cancer Center - West Harrison ( Site 0274)
    Harrison, New York 10604, United States
  • The Blavatnik Family- Chelsea Medical Center at Mount Sinai ( Site 0206)
    New York, New York 10011, United States
  • Memorial Sloan Kettering Cancer Center ( Site 0246)
    New York, New York 10022, United States
  • University of Rochester ( Site 0238)
    Rochester, New York 14642, United States
  • Memorial Sloan Kettering Cancer Center - Nassau ( Site 0275)
    Uniondale, New York 11553, United States
  • University of North Carolina- Chapel Hill ( Site 0254)
    Chapel Hill, North Carolina 27599, United States
  • Roger Maris Cancer Center ( Site 0277)
    Fargo, North Dakota 58102, United States
  • Willamette Valley Cancer Institute and Research Center ( Site 8004)
    Eugene, Oregon 97401, United States
  • Sanford Cancer Center Oncology Clinic ( Site 0205)
    Sioux Falls, South Dakota 57104, United States
  • Parkland Health & Hospital System ( Site 0272)
    Dallas, Texas 75235, United States
  • University of Texas Southwestern Medical Center ( Site 0264)
    Dallas, Texas 75390-9015, United States
  • Texas Oncology-The Woodlands ( Site 8000)
    The Woodlands, Texas 77380, United States
  • Legacy Salmon Creek Medical Center ( Site 0253)
    Vancouver, Washington 98686, United States
  • IDIM Instituto de Diagnostico e Investigaciones Metabolicas ( Site 2607)
    Caba, Buenos Aires C1012AAR, Argentina
  • Hospital Italiano de La Plata ( Site 2601)
    La Plata, Buenos Aires B1900AXI, Argentina
  • Instituto de Investigaciones Clinicas Mar del Plata ( Site 2606)
    Mar del Plata, Buenos Aires B7600FZO, Argentina
  • Hospital Aleman ( Site 2600)
    Buenos Aires, C1118AAT, Argentina
  • Hospital Italiano de Buenos Aires ( Site 2603)
    Buenos Aires, C1199ABB, Argentina
  • Centro Oncologico Riojano Integral ( Site 2605)
    La Rioja, 5300, Argentina
  • Chris OBrien Lifehouse ( Site 1605)
    Camperdown, New South Wales 2050, Australia
  • Prince of Wales Hospital [Australia] ( Site 1603)
    Randwick, New South Wales 2031, Australia
  • Royal North Shore Hospital ( Site 1600)
    St Leonards, New South Wales 2065, Australia
  • The Crown Princess Mary Cancer Centre - Westmead Hospital ( Site 1602)
    Westmead, New South Wales 2145, Australia
  • Mater Misericordiae Ltd ( Site 1608)
    South Brisbane, Queensland 4101, Australia
  • Monash Health ( Site 1606)
    Clayton, Victoria 3168, Australia
  • Epworth Freemasons Hospital ( Site 1609)
    Melbourne, Victoria 3002, Australia
  • Sir Charles Gairdner Hospital ( Site 1604)
    Nedlands, Western Australia 6009, Australia
  • Medizinische Universitat Wien ( Site 3300)
    Vienna, State of Vienna 1090, Austria
  • Universitatsklinik fuer Frauenheilkunde und Geburtshilfe ( Site 3301)
    Graz, Styria 8036, Austria
  • Medizinische Universitat Innsbruck ( Site 3302)
    Innsbruck, Tyrol 6020, Austria
  • UZA University Hospital Antwerp ( Site 3204)
    Edegem, Antwerpen 2650, Belgium
  • UZ Leuven ( Site 3200)
    Leuven, Antwerpen 3000, Belgium
  • Cliniques Universitaires Saint-Luc ( Site 3203)
    Brussels, Bruxelles-Capitale, Region de 1200, Belgium
  • AZ Maria Middelares Gent ( Site 3202)
    Ghent, Oost-Vlaanderen 9000, Belgium
  • AZ Delta ( Site 3206)
    Roeselare, West-Vlaanderen 8800, Belgium
  • Instituto do Cancer do Ceara ( Site 2703)
    Fortaleza, Ceará 60430-230, Brazil
  • Hospital Araujo Jorge Associacao de Combate ao Cancer de Goias ( Site 2702)
    Goiânia, Goiás 74605-070, Brazil
  • Faculdade de Medicina da Universidade Federal de Minas Gerais ( Site 2708)
    Belo Horizonte, Minas Gerais 30130-100, Brazil
  • Hospital de Caridade de Ijui ( Site 2712)
    Ijuí, Rio Grande do Sul 98700-000, Brazil
  • Uniao Brasileira de Educacao e Assistencia Hospital Sao Lucas da Pucrs ( Site 2701)
    Porto Alegre, Rio Grande do Sul 90610-000, Brazil
  • Hospital de Base de Sao Jose de Rio Preto ( Site 2704)
    São José do Rio Preto, São Paulo 15090-000, Brazil
  • Instituto Nacional do Cancer II ( Site 2707)
    Rio de Janeiro, 20220-410, Brazil
  • Clinica de Pesquisas e Ctro de Estudos Onc. Ginecol. e Mamaria Ltda ( Site 2706)
    São Paulo, 01317-001, Brazil
  • Real e Benemerita Associacao Portuguesa de Beneficencia ( Site 2713)
    São Paulo, 01321-001, Brazil
  • A.C. Camargo Cancer Center ( Site 2705)
    São Paulo, 01509-900, Brazil
  • Cross Cancer Institute ( Site 0408)
    Edmonton, Alberta T6G 1Z2, Canada
  • BC Cancer-Kelowna - Sindi Ahluwalia Hawkins Centre ( Site 0402)
    Kelowna, British Columbia V1Y 5L3, Canada
  • BC Cancer-Vancouver Center ( Site 0412)
    Vancouver, British Columbia V5Z 4E6, Canada
  • Juravinski Cancer Centre ( Site 0406)
    Hamilton, Ontario L8V 1C3, Canada
  • Kingston Health Sciences Centre ( Site 0401)
    Kingston, Ontario K7L 2V7, Canada
  • The Credit Valley Hospital ( Site 0403)
    Mississauga, Ontario L5M 2N1, Canada
  • Sunnybrook Research Institute ( Site 0410)
    Toronto, Ontario M4N 3M5, Canada
  • Princess Margaret Cancer Centre ( Site 0409)
    Toronto, Ontario M5G 2M9, Canada
  • CIUSSS de l Est de L Ile de Montreal - Hopital Maisonneuve-Rosemont ( Site 0414)
    Montreal, Quebec H1T 2M4, Canada
  • Centre Hospitalier de l Universite de Montreal - CHUM ( Site 0411)
    Montreal, Quebec H2X 3E4, Canada
  • McGill University Health Centre ( Site 0404)
    Montreal, Quebec H4A 3J1, Canada
  • CIUSSS de l Estrie - CHUS - Centre Hosp. Univ. Sherbrooke ( Site 0417)
    Sherbrooke, Quebec J1H 5N4, Canada
  • Anhui Provincial Cancer Hospital ( Site 2509)
    Hefei, Anhui 230001, China
  • Beijing Obstetrics and Gynecology Hospital Capital Medical University ( Site 2505)
    Beijing, Beijing Municipality 100032, China
  • Peking Union Medical College Hospital ( Site 2501)
    Beijing, Beijing Municipality 100032, China
  • Beijing Cancer Hospital ( Site 2504)
    Beijing, Beijing Municipality 100142, China
  • Chongqing Cancer Hospital ( Site 2513)
    Chongqing, Chongqing Municipality 400030, China
  • The First Affiliated Hospital.Sun Yat-sen University ( Site 2507)
    Guangzhou, Guangdong 510080, China
  • Guang Xi Tumour Hospital, Department of Chemotherapy ( Site 2517)
    Nanning, Guangxi 530021, China
  • Hubei Cancer Hospital ( Site 2510)
    Wuhan, Hubei 430079, China
  • Xiangya Hospital Central-South University ( Site 2512)
    Changsha, Hunan 410008, China
  • Nanjing Maternity and Child Health Care Hospital ( Site 2508)
    Nanjing, Jiangsu 210011, China
  • The first affiliated Hospital of Xi an Jiaotong University ( Site 2502)
    Xi'an, Shaanxi 710061, China
  • Fudan University Shanghai Cancer Center ( Site 2500)
    Shanghai, Shanghai Municipality 200032, China
  • Obstetrics and Gynecology Hosp. Fudan University ( Site 2503)
    Shanghai, Shanghai Municipality 200090, China
  • The First Affiliated Hospital of Xinjiang Medical University ( Site 2515)
    Ürümqi, Xinjiang 830054, China
  • Women s Hospital School of Medicine Zhejiang University ( Site 2511)
    Hangzhou, Zhejiang 310006, China
  • Zhejiang Cancer Hospital ( Site 2506)
    Hangzhou, Zhejiang 310022, China
  • Universitaetsmedizin Mannheim. Klinik fuer Kinder und Jugendmedizin ( Site 0622)
    Mannheim, Baden-Wurttemberg 68167, Germany
  • Universitaetsklinikum Muenster ( Site 0615)
    Münster, Baden-Wurttemberg 48149, Germany
  • Caritas-Krankenhaus St. Josef Regensburg ( Site 0613)
    Regensburg, Bavaria 93053, Germany
  • HELIOS Dr. Horst Schmidt Kliniken Wiesbaden ( Site 0623)
    Wiesbaden, Hesse 65199, Germany
  • Universitaetsklinikum Essen ( Site 0616)
    Essen, North Rhine-Westphalia 45147, Germany
  • Universitaetsklinikum Jena ( Site 0612)
    Jena, Thuringia 07747, Germany
  • Charite Universitaetsmedizin Berlin ( Site 0609)
    Berlin, 13353, Germany
  • Cork University Hospital ( Site 1400)
    Cork, T12 YE02, Ireland
  • St James Hospital ( Site 1401)
    Dublin, Dublin 8, Ireland
  • Meir Medical Center ( Site 0702)
    Kfar Saba, Central District 4428132, Israel
  • Edith Wolfson Medical Center ( Site 0703)
    Holon, Tell Abib 5822012, Israel

Showing the first 100 of 195 sites across 22 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Marth C, Moore RG, Bidzinski M, Pignata S, Ayhan A, Rubio MJ, Beiner M, Hall M, Vulsteke C, Braicu EI, Sonoda K, Wu X, Frentzas S, Mattar A, Lheureux S, Chen X, Hasegawa K, Magallanes-Maciel M, Choi CH, Shalkova M, Kaen D, Wang PH, Berger R, Okpara CE, McKenzie J, Yao L, Orlowski R, Khemka V, Gilbert L, Makker V; ENGOT-en9/LEAP-001 Investigators. First-Line Lenvatinib Plus Pembrolizumab Versus Chemotherapy for Advanced Endometrial Cancer: A Randomized, Open-Label, Phase III Trial. J Clin Oncol. 2025 Mar 20;43(9):1083-1100. doi: 10.1200/JCO-24-01326. Epub 2024 Nov 26. PubMed 39591551 ↗
  • Marth C, Lorusso D, Bidzinski M, Scollo P, Vardar MA, Oaknin A, Kaen DL, Nogueira-Rodrigues A, Miller DS, Hasegawa K, MacKay H, Moore RG, Santin AD, Yunokawa M, Romero I, Pignata S, Baron-Hay S, Kim YM, Amit A, Ghamande S, Danska-Bidzinska A, Tarnawski R, Wang PH, Yu Z, Slomovitz BM, Okpara CE, McKenzie J, Meng R, Orlowski R, Makker V. Lenvatinib plus pembrolizumab in participants with advanced or recurrent endometrial cancer: Study 309/KEYNOTE-775 and ENGOT-en9/LEAP-001 post-(neo)adjuvant therapy outcomes. Int J Gynecol Cancer. 2026 Jul;36(7):104693. doi: 10.1016/j.ijgc.2026.104693. Epub 2026 Apr 12. PubMed 42167105 ↗
  • Marth C, Moore RG, Bidzinski M, Salutari V, Altundag O, Rubio MJ, Levy T, Stillie A, Vulsteke C, Witteler R, Ariyoshi K, Wu X, Frentzas S, Mattar A, Slomovitz BM, Lheureux S, Chen X, Hasegawa K, Magallanes M, Choi CH, Shalkova M, Kaen DL, Cadoo K, Yao L, McKenzie J, Okpara CE, Meng R, Orlowski R, Gilbert L, Makker V. First-line lenvatinib plus pembrolizumab versus chemotherapy for advanced endometrial cancer: 1-Year follow-up after final analysis of the ENGOT-en9/LEAP-001 phase 3 trial. Int J Gynecol Cancer. 2026 Jan;36(1):102795. doi: 10.1016/j.ijgc.2025.102795. Epub 2025 Nov 11. PubMed 41494216 ↗
  • Marth C, Tarnawski R, Tyulyandina A, Pignata S, Gilbert L, Kaen D, Rubio MJ, Frentzas S, Beiner M, Magallanes-Maciel M, Farrelly L, Choi CH, Berger R, Lee C, Vulsteke C, Hasegawa K, Braicu EI, Wu X, McKenzie J, Lee JJ, Makker V. Phase 3, randomized, open-label study of pembrolizumab plus lenvatinib versus chemotherapy for first-line treatment of advanced or recurrent endometrial cancer: ENGOT-en9/LEAP-001. Int J Gynecol Cancer. 2022 Jan;32(1):93-100. doi: 10.1136/ijgc-2021-003017. Epub 2021 Nov 19. PubMed 34799418 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — https://trialstransparency.msdclinicaltrials.com/pdf/ProcedureAccessClinicalTrialData.pdf

Data sharing details ↗ · externaldatasharing-msd.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2019 to primary completion in Oct 2023, 53 months.

Results were first posted in Oct 2024, 1 year after primary completion.

Of 44 phase 3 interventional studies under Endometrial Neoplasms, half reached primary completion within 53 months of starting (the median), counting those still running; a quarter within 45 and three quarters within 126. This study's 53 months is close to that.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 19, 2019
First posted
Mar 21, 2019
StartActual
Apr 11, 2019
Primary completionActual
Oct 2, 2023
CompletionActual
Feb 5, 2025
Results first posted
Oct 16, 2024
Last update
Feb 2, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 2, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03884101
Collaborators
Eisai Inc.
Responsible party
Sponsor
First posted
Mar 21, 2019
Start date
Apr 11, 2019
Primary completion
Oct 2, 2023
Completion
Feb 5, 2025
Results posted
Oct 16, 2024
Last update
Feb 2, 2026

Study contacts

Medical Director
study director · Merck Sharp & Dohme LLC

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Lenvatinib · Pembrolizumab

Start the discussion